Monte Rosa pulls in $95M to test its 'molecular glues,' and the first target is GSPT1
Protein degradation has been a fundraising hotbed in recent years, with investors drooling over the potential to drug the “undruggable.” Already an investor darling, Monte Rosa Therapeutics and its “molecular glues” are going back to the well with the clinic on the horizon — and the biotech’s finally revealing its first target.
Monte Rosa hauled in a $95 million Series C to pave the way for its lead protein degrader program to make a run to the clinic and flesh out its pipeline, the biotech said Friday. The round was led by Avoro Capital Advisors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.